AR122660A2 - ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF - Google Patents
ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOFInfo
- Publication number
- AR122660A2 AR122660A2 ARP210101664A ARP210101664A AR122660A2 AR 122660 A2 AR122660 A2 AR 122660A2 AR P210101664 A ARP210101664 A AR P210101664A AR P210101664 A ARP210101664 A AR P210101664A AR 122660 A2 AR122660 A2 AR 122660A2
- Authority
- AR
- Argentina
- Prior art keywords
- antibodies
- antigen
- binding fragments
- antibody
- methods
- Prior art date
Links
Abstract
La presente solicitud describe anticuerpos anti-PMEL17, fragmentos de unión a antígeno de los mismos, y conjugados de anticuerpo fármaco de dichos anticuerpos o fragmentos de unión a antígeno conjugados a un inhibidor de GNAQ / GNA11. La invención además se refiere a métodos para tratar o prevenir el cáncer usando los anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco. Además se describen métodos de preparación de anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco, y métodos de uso de los anticuerpos y fragmentos de unión a antígeno como reactivos de diagnóstico.The present application describes anti-PMEL17 antibodies, antigen-binding fragments thereof, and antibody-drug conjugates of such antibodies or antigen-binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention further relates to methods of treating or preventing cancer using the antibodies, antigen-binding fragments, and antibody-drug conjugates. Also described are methods of preparing antibodies, antigen-binding fragments, and antibody-drug conjugates, and methods of using the antibodies and antigen-binding fragments as diagnostic reagents.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862783565P | 2018-12-21 | 2018-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR122660A2 true AR122660A2 (en) | 2022-09-28 |
Family
ID=77568195
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190103765A AR117446A1 (en) | 2018-12-21 | 2019-12-19 | ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF |
ARP210101664A AR122660A2 (en) | 2018-12-21 | 2021-06-17 | ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP190103765A AR117446A1 (en) | 2018-12-21 | 2019-12-19 | ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF |
Country Status (1)
Country | Link |
---|---|
AR (2) | AR117446A1 (en) |
-
2019
- 2019-12-19 AR ARP190103765A patent/AR117446A1/en unknown
-
2021
- 2021-06-17 AR ARP210101664A patent/AR122660A2/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR117446A1 (en) | 2021-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017004782A2 (en) | Antibody-drug conjugates | |
CL2021001607A1 (en) | Anti-pmel17 antibodies and conjugates thereof | |
CR20190346A (en) | Anti-ccr7 antibody drug conjugates | |
CL2020003071A1 (en) | Multispecific binding proteins and enhancements with them | |
BR112018006016A2 (en) | binder-drug intermediate, antibody-drug conjugate compounds, pharmaceutical compositions, methods for treating cancer, method of producing an antibody-drug conjugate and conjugate | |
CO2022002622A2 (en) | Anti-cd73 antibodies and compositions | |
CO2022009696A2 (en) | Anti-lilrb1 antibody and uses thereof | |
BR112018072118A2 (en) | interferon beta antibodies and their uses | |
CL2021001593A1 (en) | Tubulisins and protein-tubulisin conjugates | |
BR112021025720A2 (en) | Antitissue factor antibody-drug conjugates and related methods | |
CO2022002573A2 (en) | Antibodies against ilt2 and their use | |
WO2018089807A3 (en) | Anti-cd46 antibodies and methods of use | |
BR112021016596A2 (en) | Anti-pd-l1 antibody and its use | |
CL2021003215A1 (en) | Anti-pcrv antibodies that bind to pcrv, compositions comprising anti-pcrv antibodies, and methods of using these | |
CO2023002375A2 (en) | Antibodies against ilt2 and use thereof | |
BR112022008756A2 (en) | ANTI-MESOTHELIN ERIBULIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | |
EA201992315A1 (en) | COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER | |
BR112022009672A2 (en) | TREATMENT OF CANCER WITH ANTIBODY-DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS | |
AR122660A2 (en) | ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF | |
MX2020003806A (en) | Dna monoclonal antibodies targeting ctla-4 for the treatment and prevention of cancer. | |
CL2022001937A1 (en) | Anti-pmel17 antibodies and conjugates thereof (divisional 202101607) | |
EA202192173A1 (en) | ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES | |
AR115987A1 (en) | ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | |
AR118787A1 (en) | PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES | |
AR121317A2 (en) | ANTI-HTRA1 ANTIBODIES AND METHODS OF USE THEREOF |